0001104659-18-025834.txt : 20180423 0001104659-18-025834.hdr.sgml : 20180423 20180423160546 ACCESSION NUMBER: 0001104659-18-025834 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180412 FILED AS OF DATE: 20180423 DATE AS OF CHANGE: 20180423 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Iannone Robert CENTRAL INDEX KEY: 0001737329 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 18768966 MAIL ADDRESS: STREET 1: 300 THE AMERICAN WAY CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 3 1 a3.xml 3 X0206 3 2018-04-12 0 0000722830 IMMUNOMEDICS INC IMMU 0001737329 Iannone Robert C/O IMMUNOMEDICS, INC 300 THE AMERICAN ROAD MORRIS PLAINS NJ 07950 0 1 0 0 See Remarks Stock Options (right to buy) 14.46 2025-04-09 Common Stock, par value $0.01 per share 110000 D Stock Options (right to buy) 14.46 2025-04-09 Common Stock, par value $0.01 per share 70000 D Stock Options (right to buy) 14.46 2025-04-09 Common Stock, par value $0.01 per share 140000 D The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter. The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 70,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $28.92 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 70,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $43.38 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date. If the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, and to the extent such performance-based vesting criteria is subsequently attained, the applicable tranche of stock options may vest on the date such criteria is met. Mr. Iannone is the Issuer's Chief Medical Officer. The Issuer's Board of Directors identified Mr. Iannone as a Section 16 Reporting Person on April 12, 2018. /s/Robert Iannone 2018-04-23